Dose Ranging Study in Elective Total Hip Replacement Surgery
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The primary objective is to:
- demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE)
by the demonstration of a dose-response in patients undergoing total hip replacement
surgery.
The secondary objectives are to:
- evaluate the safety of SR123781A in the prevention of VTE after elective total hip
replacement surgery; and
- to assess the SR123781A pharmacokinetic profile in patients undergoing elective total
hip replacement surgery.